COMP <GO>
ALDX vs SCYX // RETURN ON INVESTED CAPITAL (ROIC)
Aldeyra Therapeutics Inc. (NASDAQ) VS. SCYNEXIS Inc. (NASDAQ) • 15-METRIC TALLY: ALDX 1
— SCYX 1
■ METRIC PARITY
LAST: $0.56 (-14.99%) • MKT CAP: $39.8M
roic
-35.00%
LAST: $3.77 (-2.33%) • MKT CAP: $38.4M
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALDX VS. SCYX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALDX | SCYX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -13.76% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -41.80% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 4/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.4 | 41.3 | -5.90 | SCYX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $39.8M | $38.4M | $1.4M | ALDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALDX REV | SCYX REV | ALDX GROSS % | SCYX GROSS % | ALDX FCF | SCYX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $20.6M | — | — | -$33.3M | -$5.3M |
| FY 2024 | $0 | $3.7M | — | — | -$43.2M | -$24.0M |
| FY 2023 | $0 | $140.1M | — | — | -$30.3M | $60.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALDX // BETA —
SCYX // BETA —